KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

CRISPR Therapeutics AG (CRSP) Net Income towards Common Stockholders (2016 - 2025)

Historic Net Income towards Common Stockholders for CRISPR Therapeutics AG (CRSP) over the last 11 years, with Q3 2025 value amounting to -$106.4 million.

  • CRISPR Therapeutics AG's Net Income towards Common Stockholders fell 2381.76% to -$106.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$530.0 million, marking a year-over-year decrease of 9603.28%. This contributed to the annual value of -$408.0 million for FY2024, which is 12125.16% down from last year.
  • As of Q3 2025, CRISPR Therapeutics AG's Net Income towards Common Stockholders stood at -$106.4 million, which was down 2381.76% from -$208.6 million recorded in Q2 2025.
  • Over the past 5 years, CRISPR Therapeutics AG's Net Income towards Common Stockholders peaked at $759.2 million during Q2 2021, and registered a low of -$208.6 million during Q2 2025.
  • For the 5-year period, CRISPR Therapeutics AG's Net Income towards Common Stockholders averaged around -$69.4 million, with its median value being -$113.2 million (2021).
  • As far as peak fluctuations go, CRISPR Therapeutics AG's Net Income towards Common Stockholders soared by 105287.85% in 2021, and later tumbled by 23481.09% in 2024.
  • CRISPR Therapeutics AG's Net Income towards Common Stockholders (Quarter) stood at -$141.2 million in 2021, then rose by 20.1% to -$112.9 million in 2022, then skyrocketed by 151.93% to $58.6 million in 2023, then tumbled by 234.81% to -$79.0 million in 2024, then plummeted by 34.71% to -$106.4 million in 2025.
  • Its Net Income towards Common Stockholders stands at -$106.4 million for Q3 2025, versus -$208.6 million for Q2 2025 and -$136.0 million for Q1 2025.